Th17細胞如何通過腫瘤微環境促進肺癌血管形成？_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

杜威 ,  時國朝

上海交通大學醫學院附屬瑞金醫院呼吸科 (上海 200025);

Corresponding?author：

時國朝, Email: shi_guochao@yahoo.com

Keywords：

DOI：

10.7507/1671-6205.2015104

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 杜威, 時國朝. Th17細胞如何通過腫瘤微環境促進肺癌血管形成？. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(4): 417-420. doi: 10.7507/1671-6205.2015104 Copy

1.	Hemdan NY.Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells.Immunol Lett, 2013, 149:123-133.
2.	Murugaiyan G, Saha B.Protumor vs antitumor functions of IL-17.J Immunol, 2009, 183:4169-4175.
3.	O'Connor SJ.Review of the incidence, prevalence, mortality and causative factors for lung cancer in Europe.Eur J Cancer, 2011, 47, Supplement 3:S346-S347.
4.	昌盛, 代敏, 任建松, 等.中國2008年肺癌發病、死亡和患病情況的估計及預測.中華流行病學雜志, 2012, 33:391-394.
5.	Tartour E, Pere H, Maillere B, et al.Angiogenesis and immunity:a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Cancer Metastasis Rev, 2011, 30:83-95.
6.	Horn L, Sandler AB.Angiogenesis in the treatment of non-small cell lung cancer.Proc Am Thorac Soc, 2009, 6:206-217.
7.	Wilke C, Zou W.TH17 cells in the tumor micro-environment.in:TH17 Cells in Health and Disease.New York:Springer Press, 2011, 481-496.
8.	Kim JS, Jordan MS.Diversity of IL-17-producing T lymphocytes.Cell Mol Life Sci, 2013, 70:2271-2290.
9.	Kryczek I, Banerjee M, Cheng P, et al.Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.Blood, 2009, 114:1141-1149.
10.	Zhang GQ, Han F, Fang XZ, et al.CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis.Asian Pac J Cancer Prev, 2012, 13:3955-3960.
11.	Gaffen SL.An overview of IL-17 function and signaling.Cytokine, 2008, 43:402-407.
12.	Wilke CM, Kryczek I, Wei S, et al.Th17 cells in cancer:help or hindrance? Carcinogenesis, 2011, 32:643-649.
13.	Hus I, Maciag E, Roliński J.The role of Th17 cells in anti-cancer immunity.Postepy Hig Med Dosw(Online), 2010, 64:244-250.
14.	Neurath MF, Finotto S.The emerging role of T cell cytokines in non-small cell lung cancer.Cytokine Growth Factor Rev, 2012, 23:315-322.
15.	Chang SH, Mirabolfathinejad SG, Katta H, et al.T helper 17 cells play a critical pathogenic role in lung cancer.Proc Natl Acad Sci U S A, 2014, 111:5664-5669.
16.	Castermans K, Tabruyn SP, Zeng R, et al.Angiostatic activity of the antitumor cytokine interleukin-21.Blood, 2008, 112:4940-4947.
17.	Ramesh R, Mhashilkar AM, Tanaka F, et al.Melanoma differentiation-associated gene 7/Interleukin(IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.Cancer Res, 2003, 63:5105-5113.
18.	Numasaki M, Fukushi J, Ono M, et al.Interleukin-17 promotes angiogenesis and tumor growth.Blood, 2003, 101:2620-2627.
19.	Dimova I, Popivanov G, Djonov V.Angiogenesis in cancer-general pathways and their therapeutic implications.J BUON, 2014, 19:15-21.
20.	Koyama K, Kagamu H, Miura S, et al.Reciprocal CD4⁺ T-cell balance of effector CD62^low CD4⁺ and CD62L^highCD25⁺ CD4⁺ regulatory T cells in small cell lung cancer reflects disease stage.Clin Cancer Res, 2008, 14:6770-6779.
21.	何改平, 張彬, 張寶文, 等.肺癌腦轉移患者Th17細胞和IL-17水平變化的研究.中國肺癌雜志, 2013, 16:476-481.
22.	Shi W, Li X, Cha Z, et al.Dysregulation of circulating follicular helper T cells in nonsmall cell lung cancer.DNA Cell Biol, 2014, 33:355-360.
23.	Zhao L, Yang J, Wang HP, et al.Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma.Med Oncol, 2013, 30:461.
24.	Brussino L, Culla B, Bucca C, et al.Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer.J Breath Res, 2014, 8:27110.
25.	Numasaki M, Lotze MT, Sasaki H.Interleukin-17 augments tumor necrosis factor-α-induced elaboration of proangiogenic factors from fibroblasts.Immuno Lett, 2004, 93:39-43.
26.	Li Y, Cao ZY, Sun B, et al.Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther, 2011, 12:610-616.
27.	Honorati MC, Neri S, Cattini L, et al.Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts.Osteoarthritis Cartilage, 2006, 14:345-352.
28.	Kuang DM, Zhao Q, Wu Y, et al.Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma.J Hepatol, 2011, 54:948-955.
29.	Pickens SR, Volin MV, Mandelin AN, et al.IL-17 contributes to angiogenesis in rheumatoid arthritis.J Immunol, 2010, 184:3233-3241.
30.	Yang CL, Liu YY, Ma YG, et al.Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway.PLoS One, 2012, 7:e37960.
31.	Atsumi T, Singh R, Sabharwal L, et al.Inflammation amplifier, a new paradigm in cancer biology.Cancer Res, 2014, 74:8-14.
32.	Tecchio C, Cassatella MA.Neutrophil-derived cytokines involved in physiological and pathological angiogenesis.Chem Immunol Allergy, 2014, 99:123-137.
33.	Numasaki M, Watanabe M, Suzuki T, et al.IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.J Immunol, 2005, 175:6177-6189.
34.	Hymowitz SG, Filvaroff EH, Yin JP, et al.IL-17s adopt a cystine knot fold:structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.EMBO J, 2001, 20:5332-5341.
35.	Starnes T, Robertson M J, Sledge G, et al.Cutting edge:IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production.J Immunol, 2001, 167:4137-4140.
36.	Xie Y, Sheng W, Xiang J, et al.Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis.Cancer Invest, 2010, 28:598-607.
37.	Lim C, Savan R.The role of the IL-22/IL-22R1 axis in cancer.Cytokine Growth Factor Rev, 2014, 25:257-271.
38.	Weber GF, Gaertner FC, Erl W, et al.IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase.J Immunol, 2006, 177:8266-8272.
39.	Loeffler S, Fayard B, Weis J, et al.Interleukin-6 induces transcriptional activation of vascular endothelial growth factor(VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1.Int J Cancer, 2005, 115:202-213.
40.	Yao JS, Zhai W, Young WL, et al.Interleukin-6 triggers human cerebral endothelial cells proliferation and migration:the role for KDR and MMP-9.Biochem Biophys Res Commun, 2006, 342:1396-1404.
41.	Guo Y, Xu F, Lu T, et al.Interleukin-6 signaling pathway in targeted therapy for cancer.Cancer Treat Rev, 2012, 38:904-910.
42.	Kume T.Ligand-dependent Notch signaling in vascular formation.Adv Exp Med Biol, 2012, 727:210-222.
43.	Wu Y, Zhou BP.TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion.Br J Cancer, 2010, 102:639-644.
44.	Sun L, Zhang S, Jiang Z, et al.Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-α-treated A549 cells.Biochem Biophys Res Commun, 2011, 416:99-105.
45.	Liu L, Ge D, Ma L, et al.Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer.J Thorac Oncol, 2012, 7:1091-1100.
46.	Baird A, Dockry é, Daly A, et al.IL-23R is epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer.Front Oncol, 2013, 3:162.

1. Hemdan NY.Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells.Immunol Lett, 2013, 149:123-133.
2. Murugaiyan G, Saha B.Protumor vs antitumor functions of IL-17.J Immunol, 2009, 183:4169-4175.
3. O'Connor SJ.Review of the incidence, prevalence, mortality and causative factors for lung cancer in Europe.Eur J Cancer, 2011, 47, Supplement 3:S346-S347.
4. 昌盛, 代敏, 任建松, 等.中國2008年肺癌發病、死亡和患病情況的估計及預測.中華流行病學雜志, 2012, 33:391-394.
5. Tartour E, Pere H, Maillere B, et al.Angiogenesis and immunity:a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Cancer Metastasis Rev, 2011, 30:83-95.
6. Horn L, Sandler AB.Angiogenesis in the treatment of non-small cell lung cancer.Proc Am Thorac Soc, 2009, 6:206-217.
7. Wilke C, Zou W.TH17 cells in the tumor micro-environment.in:TH17 Cells in Health and Disease.New York:Springer Press, 2011, 481-496.
8. Kim JS, Jordan MS.Diversity of IL-17-producing T lymphocytes.Cell Mol Life Sci, 2013, 70:2271-2290.
9. Kryczek I, Banerjee M, Cheng P, et al.Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.Blood, 2009, 114:1141-1149.
10. Zhang GQ, Han F, Fang XZ, et al.CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis.Asian Pac J Cancer Prev, 2012, 13:3955-3960.
11. Gaffen SL.An overview of IL-17 function and signaling.Cytokine, 2008, 43:402-407.
12. Wilke CM, Kryczek I, Wei S, et al.Th17 cells in cancer:help or hindrance? Carcinogenesis, 2011, 32:643-649.
13. Hus I, Maciag E, Roliński J.The role of Th17 cells in anti-cancer immunity.Postepy Hig Med Dosw(Online), 2010, 64:244-250.
14. Neurath MF, Finotto S.The emerging role of T cell cytokines in non-small cell lung cancer.Cytokine Growth Factor Rev, 2012, 23:315-322.
15. Chang SH, Mirabolfathinejad SG, Katta H, et al.T helper 17 cells play a critical pathogenic role in lung cancer.Proc Natl Acad Sci U S A, 2014, 111:5664-5669.
16. Castermans K, Tabruyn SP, Zeng R, et al.Angiostatic activity of the antitumor cytokine interleukin-21.Blood, 2008, 112:4940-4947.
17. Ramesh R, Mhashilkar AM, Tanaka F, et al.Melanoma differentiation-associated gene 7/Interleukin(IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.Cancer Res, 2003, 63:5105-5113.
18. Numasaki M, Fukushi J, Ono M, et al.Interleukin-17 promotes angiogenesis and tumor growth.Blood, 2003, 101:2620-2627.
19. Dimova I, Popivanov G, Djonov V.Angiogenesis in cancer-general pathways and their therapeutic implications.J BUON, 2014, 19:15-21.
20. Koyama K, Kagamu H, Miura S, et al.Reciprocal CD4⁺ T-cell balance of effector CD62^low CD4⁺ and CD62L^highCD25⁺ CD4⁺ regulatory T cells in small cell lung cancer reflects disease stage.Clin Cancer Res, 2008, 14:6770-6779.
21. 何改平, 張彬, 張寶文, 等.肺癌腦轉移患者Th17細胞和IL-17水平變化的研究.中國肺癌雜志, 2013, 16:476-481.
22. Shi W, Li X, Cha Z, et al.Dysregulation of circulating follicular helper T cells in nonsmall cell lung cancer.DNA Cell Biol, 2014, 33:355-360.
23. Zhao L, Yang J, Wang HP, et al.Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma.Med Oncol, 2013, 30:461.
24. Brussino L, Culla B, Bucca C, et al.Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer.J Breath Res, 2014, 8:27110.
25. Numasaki M, Lotze MT, Sasaki H.Interleukin-17 augments tumor necrosis factor-α-induced elaboration of proangiogenic factors from fibroblasts.Immuno Lett, 2004, 93:39-43.
26. Li Y, Cao ZY, Sun B, et al.Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther, 2011, 12:610-616.
27. Honorati MC, Neri S, Cattini L, et al.Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts.Osteoarthritis Cartilage, 2006, 14:345-352.
28. Kuang DM, Zhao Q, Wu Y, et al.Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma.J Hepatol, 2011, 54:948-955.
29. Pickens SR, Volin MV, Mandelin AN, et al.IL-17 contributes to angiogenesis in rheumatoid arthritis.J Immunol, 2010, 184:3233-3241.
30. Yang CL, Liu YY, Ma YG, et al.Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway.PLoS One, 2012, 7:e37960.
31. Atsumi T, Singh R, Sabharwal L, et al.Inflammation amplifier, a new paradigm in cancer biology.Cancer Res, 2014, 74:8-14.
32. Tecchio C, Cassatella MA.Neutrophil-derived cytokines involved in physiological and pathological angiogenesis.Chem Immunol Allergy, 2014, 99:123-137.
33. Numasaki M, Watanabe M, Suzuki T, et al.IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.J Immunol, 2005, 175:6177-6189.
34. Hymowitz SG, Filvaroff EH, Yin JP, et al.IL-17s adopt a cystine knot fold:structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.EMBO J, 2001, 20:5332-5341.
35. Starnes T, Robertson M J, Sledge G, et al.Cutting edge:IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production.J Immunol, 2001, 167:4137-4140.
36. Xie Y, Sheng W, Xiang J, et al.Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis.Cancer Invest, 2010, 28:598-607.
37. Lim C, Savan R.The role of the IL-22/IL-22R1 axis in cancer.Cytokine Growth Factor Rev, 2014, 25:257-271.
38. Weber GF, Gaertner FC, Erl W, et al.IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase.J Immunol, 2006, 177:8266-8272.
39. Loeffler S, Fayard B, Weis J, et al.Interleukin-6 induces transcriptional activation of vascular endothelial growth factor(VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1.Int J Cancer, 2005, 115:202-213.
40. Yao JS, Zhai W, Young WL, et al.Interleukin-6 triggers human cerebral endothelial cells proliferation and migration:the role for KDR and MMP-9.Biochem Biophys Res Commun, 2006, 342:1396-1404.
41. Guo Y, Xu F, Lu T, et al.Interleukin-6 signaling pathway in targeted therapy for cancer.Cancer Treat Rev, 2012, 38:904-910.
42. Kume T.Ligand-dependent Notch signaling in vascular formation.Adv Exp Med Biol, 2012, 727:210-222.
43. Wu Y, Zhou BP.TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion.Br J Cancer, 2010, 102:639-644.
44. Sun L, Zhang S, Jiang Z, et al.Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-α-treated A549 cells.Biochem Biophys Res Commun, 2011, 416:99-105.
45. Liu L, Ge D, Ma L, et al.Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer.J Thorac Oncol, 2012, 7:1091-1100.
46. Baird A, Dockry é, Daly A, et al.IL-23R is epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer.Front Oncol, 2013, 3:162.

Previous Article
細胞膜微粒在急性呼吸窘迫綜合征中作用的研究現狀
Next Article
腫瘤化療患者經外周中心靜脈置管相關血栓形成的因素及防治

Chinese Journal of Respiratory and Critical Care Medicine

Th17細胞如何通過腫瘤微環境促進肺癌血管形成？

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content